The capacity of such signaling molecules to affect phosphorylation ERK1/2 and leukemia-cell proliferation, however, is dependent on kinases such as BTK, which can be inhibited by ibrutinib [44, 45], potentially accounting for the noted clinical activity of this drug in the treatment of patients with CLL. This evidence concerns the gene MAPK3 and B-cell chronic lymphocytic leukemia.